Barriers to successful transplantation of the sensitized patient

Expert Review of Clinical Immunology

Volumn 6, Issue 3, 2010, Pages 449-460

  Zachary, Andrea A ^a   Leffell, Mary S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acceptable mismatch; Antibodies; Crossmatch; Desensitization; HLA; IVIg; Plasmapheresis; Sensitization; Solid phase immunoassays; Unacceptable antigens

Indexed keywords

BORTEZOMIB; CYTOMEGALOVIRUS ANTIBODY; ECULIZUMAB; HLA ANTIBODY; HLA DP ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP ABO SYSTEM; DESENSITIZATION; DOWN REGULATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT SURVIVAL; HEART GRAFT; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PLASMAPHERESIS; REVIEW; TRANSPLANTATION;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES; BLOOD GROUP INCOMPATIBILITY; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MULTICENTER STUDIES AS TOPIC; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952041825     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.14     Document Type: Review

References (87)

1. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates TH. Clinical significance of anti-HLA antibodies detected by Luminex®: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools. Hum. Immunol. 70 (8), 595-599 (2009).
2. Lee PC, Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. In: Clinical Transplants 2007. Cecka JM, Terasaki PI (Eds). Terasaki Foundation Laboratory, CA, USA, 219-226 (2008).
3. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specfic antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol. Dial. Transplant. 21 (9), 2625-2629 (2006).
4. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Hum. Immunol. 66 (4), 364-370 (2005).
5. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum. Immunol. 70 (8), 584-588 (2009).
6. Zachary AA, Montgomery RA, Leffell MS. Defning unacceptable HLA antigens. Curr. Opin. Organ. Transplant. 13 (4), 405-410 (2008).
7. Zachary AA, Braun WE. Calculation of a predictive value for transplantation. Transplantation 39 (3), 316-318 (1985).
8. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigenspecific antibodies. Hum. Immunol. 69 (10), 591-604 (2008).
9. Zeevi A, Lunz JG III, Shapiro R et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum. Immunol. 70 (8), 645-650 (2009).
10. Samaniego M, Mezrich J, Torrealba J et al. C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin Experience. In: Clinical Transplants 2006. Terasaki PI (Ed.). Terasaki Foundation Laboratory, CA, USA, 503-507 (2007). •• Early report of the clinical significance of do nor-specific antibodies limited to donor HLA-DP. This report also includes data about the frequency of DP-specific antibodies among sensitized patients.
11. Thaunat O, Hanf W, Dubois V et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donorspecific alloantibodies generation. Transpl. Immunol. 20 (4), 209-211 (2009).
12. Vaidya S, Hilson B, Sheldon S, Cano P, Fernandez-Vina M. DP reactive antibody in a zero mismatch renal transplant pair. Hum. Immunol. 68 (12), 947-949 (2007). • Demonstrates that antibodies to donor HLA-DP can be detected in a flow cytometric crossmatch.
13. Pfeiffer K, Vögeler U, Albrecht KH, Eigler FW, Buchholz B, Grosse-Wilde H. HLA-DP antibodies in patients awaiting renal transplantation. Transpl. Int. 8 (3), 180-184 (1995).
14. Callender CJ, Chesterton KA, Kaplan I, Leffell MS, Zachary AA. Frequency of DP antibodies. Hum. Immunol. 69 (1 Suppl.), S11 (2008).
15. Stastny P, Zou Y, Fan Y, Qin Z, Lavingia B. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib. Nephrol. 162, 99-106 (2009). •• This is one of many studies from a group with extensive experience with MHC class I chain-related gene A (MICA) and endothelial antigens. Reviews current knowledge and the clinical potential of such antibodies.
16. Mizutani K, Terasaki P, Bignon JD et al. Association of kidney transplant failure and antibodies against MICA. Hum. Immunol 67 (9), 683-691 (2006).
17. Sumitran-Holgersson S, Wilczek HE, Holgersson J, Söderström K. Identifcation of the nonclassical HLA molecules, MICA, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2), 268-277 (2002).
18. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transpl ant rejection. N. Engl. J. Med. 357 (13), 1293-1300 (2007).
19. Terasaki PI, Ozawa M, Castro R. Four year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am. J. Transplant. 7 (2), 408-415 (2007).
20. Zou Y, Heinemann FM, Grosse-Wilde H et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum. Immunol. 67 (3), 230-237 (2006). • Provides conclusive evidence of the role of MICA-specific antibodies in renal transplantation.
21. Stastny P, Zou Y, Fan Y, Qin Z, Lavingia B. The emerging issue of MICA antibodies: antibodies to MICA and other antigens of endothelial cells. Contrib. Nephrol. 162, 99-106 (2009).
22. Smith JD, Brunner VM, Jigidsuren S et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am. J. Transplant. 9 (8), 1912-1919 (2009).
23. Breimer ME, Rydberg L, Jackson AM et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 87 (4), 549-556 (2009). •• Report from a multicenter study of the clinical relevance of ant i-endothelial antibodies detected in a flow cytometric crossmatch performed on precursor endothelial cells obtained from peripheral blood.
24. Stastny P, Ring S, Lu C, Arenas J, Han M, Lavingia B. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum. Immunol. 70 (8), 600-604 (2009).
25. Suzuki M, Ishida H, Komatsu T, Kennoki T, Ishizuka T, Tanabe K. Kidney transplantation in a recipient with anti-HLA antibody IgM positive. Transpl Immunol. 21 (3), 150-154 (2009).
26. Mai ML, Ahsan N, Wadei HM et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 87 (2), 227-232 (2009).
27. O'Rourke RW, Osorio RW, Freise CE et al. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin. Transplant. 14 (2), 167-173 (2000).
28. Wen R, Wu V, Dmitrienko S, Yu A, Balshaw R, Keown PA. Biomarkers in transplantation: prospective, blinded measurement of predictive value for the fow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. Kidney Int. 70 (8), 1474-1481 (2006).
29. Süsal C, Döhler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a Collaborative Transplant Study report. Transplantation 87 (9), 1367-1371 (2009).
30. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib. Nephrol. 162, 1-12 (2009).
31. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen fow-beads. Transplantation 87 (11), 1681-1688 (2009).
32. Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum. Immunol. 70 (8), 618-622 (2009).
33. Vlad G, Ho EK, Vasilescu E et al. Relevance of different antibody detection methods for the prediction of antibodymediated rejection and deceased-donor kidney allograft survival. Hum. Immunol 70 (8), 589-594 (2009).
34. Zachary AA, Montgomery RA, Jordan SC, Reinsmoen NL, Claas FHJ, Reed EF. 14th International HLA and Immunogenetics Workshop: report on understanding antibodies in transplantation. Tissue Antigens. 69 (1 Suppl.), 160-173 (2007).
35. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr. Transplant. 8, 535-542 (2004).
36. Leffell M, Locke J, Houp J, Montgomery R, Zachary A. Successful transplantation of patients with low level donor HLA specific antibody without desensitization treatment. Transplantation 86 (2 Suppl.), 184 (2008).
37. Jindra PT, Zhang X, Mulder A et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 82 (1S), S33-S35 (2006). •• One of a series of papers from this group showing that signaling that occurs as the result of HLA-specific antibody binding can have two different results related to the amount of bound antibody. Provides evidence at the molecular level for the mechanism of chronic rejection.
38. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T. Pre-exposure to sub-saturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur. J. Immunol 34 (8), 2303-2312 (2004).
39. Arnold ML, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complementbinding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens 72 (1), 60-66 (2008).
40. Rose ML, Smith JD. Clinical relevance of complement-fxing antibodies in cardiac transplantation. Hum. Immunol. 70 (8), 605-609 (2009). • Shows that the results of a multianalyte bead assay modifed to detect complement activation by HLA-specific antibody correlate with transplant outcome.
41. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex® assays for HLA-specific antibodies: characteristics and resolution. Hum. Immunol. 70 (7), 496-501 (2009).
42. Warner P. Nebulous humors: defning alloantibodies in the 21st century. Hum. Immunol. 70 (8), 623-626 (2009).
43. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 86, 384-390 (2008).
44. Lachmann N, Terasaki P, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 87 (10), 1505-1513 (2009).
45. Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 79 (5), 591-598 (2005).
46. Mihaylova A, Baltadjieva D, Boneva P et al. Clinical relevance of anti-HLA antibodies detected by fow-cytometry bead-based assays-single-center experience. Hum. Immunol. 67 (10), 787-794 (2006).
47. Ozawa M, Terasaki PI, Castro R et al. 14th International HLA and Immunogenetics Workshop Prospecitve Chronic Rejection Project: a three-year follow-up analysis. In: Clinical Transplants 2007. Cecka JM, Terasaki PI (Eds). Terasaki Foundation Laboratory, CA, USA, 255-260 (2008).
48. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 86, 377-383 (2008).
49. Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr. Opin. Immunol. 21, 1-4 (2009).
50. Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78 (2), 190-193 (2004). •• Describes a method for circumventing the humoral barrier by identifying acceptable or safe mismatches. Demonstrates that this approach increases the frequency of transplantation among sensitized patients.
51. Zachary AA, Kopchaliiska D, Montgomery RA, Leffell MS. HLA-specific B cells: II. Application to transplantation. Transplantation 83, 989-994 (2006). •• Report of the use of a novel technique to quantify HLA-specific antibodies in order to identify cryptic sensitization in patients lacking antibody to donor HLA.
52. Roodnat JI, Kal-van Gestel JA, Zuidema W et al. Successful expansion of the living donor pool by alternative living donation programs. Am. J. Transplant. 9 (9), 2150-2156 (2009).
53. Ferrari P, Woodroffe C, Christiansen FT. Paired kidney donations to expand the living donor pool: the Western Australian experience. Med. J. Aust. 190 (12), 700-703 (2009).
54. Hanto RL, Reitsma W, Delmonico FL. The development of a successful multiregional kidney paired donation program. Transplantation 86 (12), 1744-1748 (2008).
55. Montgomery RA, Katznelson S, Bry WI et al. Successful three-way kidney paired donation with cross-country live donor allograft transport. Am. J. Transplant. 8 (10), 2163-2168 (2008).
56. Gentry SE, Segev DL, Simmerling M, Montgomery RA. Expanding kidney paired donation through participation by compatible pairs. Am. J. Transplant. 7 (10), 2361-2370 (2007). • Expands the paradigm of paired donation through inclusion of compatible pairs.
57. Gentry SE, Montgomery RA, Swihart BJ, Segev DL. The roles of dominos and nonsimultaneous chains in kidney paired donation. Am. J. Transplant. 9 (6), 1330-1336 (2009).
58. Rees MA, Kopke JE, Pelletier RP et al. A nonsimultaneous, extended, altruisticdonor chain. N. Engl. J. Med. 360 (11), 1096-1101 (2009). • Demonstrates a modification of paired donation that both increases the number of patients transplanted and eliminates the need for simultaneous transplant surgeries.
59. Kaplan I, Houp JA, Montgomery RA, Leffell MS, Hart JM, Zachary AA. A computer program for paired and unconventional kidney exchange. Am. J. Transplant. 5 (9), 2306-2308 (2005).
60. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to decreased donor kidney transplantation. Transplantation 86 (12), 1864-1868 (2008).
61. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum. Immunol. 70 (8), 574-578 (2009).
62. Appel JZ 3rd, Hartwig MG, Cantu E 3rd, Palmer SM, Reinsmoen NL, David RD. Role of flow cytometry to defne unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 81, 1049-1057 (2006). • Shows that use of the virtual crossmatch can increase the geographic area from which organs with short allowable cold ischemia times can be procured.
63. Jordan SC, Tyan D, Stablein D et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J. Am. Soc. Nephrol. 15 (12), 3256-3262 (2004). •• Describes the use of high-dose intravenous immunoglobulin for desensitization and its possible mechanisms.
64. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359 (3), 242-251 (2008).
65. Zachary AA, Montgomery RA, Ratner LE et al. Specific and durable elimination of antibody to donor HLA antigen in renal transplant patients. Transplantation 76 (10), 1519-1525 (2003).
66. Montgomery RA, Locke JE, King KE et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 87 (8), 1246-1255 (2009). •• Presents a new paradigm for ABO-incompatible transplantation without the use of splenectomy or B-celldepleting agents.
67. Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 87 (12), 1837-1841 (2009).
68. Billing H, Rieger S, Ovens J et al. Successful treatment of chronic antibodymediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 86 (9), 1214-1221 (2008).
69. Jordan SC, Quartel AW, Czer LS et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 (6), 800-805 (1998).
70. Rocha PN, Butterly DW, Greenberg A et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 75 (9), 1490-1495 (2003).
71. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchpositive recipients. Transplantation 70 (6), 887-895 (2000).
72. Ibernón M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant. Proc. 37 (9), 3743-3745 (2005).
73. Lehrich RW, Rocha PN, Reinsmoen N et al. Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. Human Immunol. 66 (4), 350-358 (2005).
74. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am. J. Transplant. 8 (12), 2607-2617 (2008).
75. Becker Y T, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am. J. Transplant. 4 (6), 996-1001 (2004).
76. Montgomery R, Simpkins C, Zachary A et al. Anti-CD20 rescue therapy for refractory kidney transplant rejection. Am. J. Transplant. 4 (Suppl. 8), 258 (2004).
77. Mulley WR, Hudson FJ, Tait BD et al. A single low-fxed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 87 (2), 286-289 (2009).
78. Locke JE, Magro CM, Singer AL et al. The use of antibody to complement protein C5 for salvage treatment of severe antibodymediated rejection. Am. J. Transplant. 9 (1), 231-235 (2009). • Early description of the use of a complement inhibitor to rescue a graft undergoing severe antibody-mediated rejection.
79. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy Transplantation 83 (1), 99-100 (2007).
80. Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am. J. Transplant. 7 (4), 842-846 (2007).
81. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 9 (1), 201-209 (2009).
82. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specifc antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9 (5), 1063-1071 (2009).
83. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86 (12), 1754-1761 (2008). •• Describes the use of a proteosome inhibitor to block antibody production and its utility in resolving both antibody-and cell-mediated rejection.
84. Everly MJ, Everly JJ, Susskind B et al. Proteasome inhibition reduces donorspecific antibody levels. Transplant. Proc. 41 (1), 105-107 (2009).
85. Locke JE, Zachary AA, Warren DS et al. Proinfammatory events are associated with significant increases in breadth and strength of HLA-specific antibody Am. J. Transplant. 9, 2136-2139 (2009).
86. Leffell MS, Zachary AA. The role of the histocompatibility laboratory in desensitization for transplantation. Curr. Opin. Organ. Transplant. 14, 398-402 (2009).
87. Reinsmoen NL, Lai CH, Vo A et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86 (6), 820-825 (2008). •• Demonstrates the use of the virtual crossmatch to predict the safety of transplantation after desensitization.